Patent Portfolio Overview
ImmunoBrain Checkpoint is developing a pipeline of novel immune therapies to treat neurodegeneration and other forms of brain disorders by harnessing peripheral immunity.
![](https://immunobrain.com/wp-content/uploads/2023/12/h6.jpg)
The ImmunoBrain team and Prof. Schwartz group at the Weizmann Institute of Science, were the first to demonstrate that targeting specific immune checkpoint pathways can be utilized as a therapeutic approach for neurodegenerative disease. Based on these findings, ImmunoBrain has been developing several patent families.
First is our platform IP, a portfolio of use/method patents covering a wide range of immune checkpoint inhibitors for the treatment of neurodegenerative disorders. Additional patent families cover a proprietary fully human anti-PD-L1 antibody, IBC-Ab002. This antibody was designed with specific modifications based on its intended mechanism of action, and tailored for treatment of neurodegenerative diseases.